GlaxoSmithKline Czech Republic's total assets reached CZK 1,520 mil at the end of 2017, down 0.266% compared to the previous year.
Current assets amounted to CZK 1,496 mil, or 98.4% of total assets while cash stood at CZK 209 mil at the end of 2017.
By contrast, total debt reached CZK 0 mil at the year-end, or 0% of total assets, while the firm's equity amounted to CZK 1,520 mil. As a result, net debt stood at CZK -209 mil at the end of 2017 and accounted for -13.8% of equity.
Net debt against equity is down 31.3 pp from five years ago (17.5%). The ratio against EBITDA decreased from 1.02x seen in 2012 to -2.15x.
The company’s cost of funding amounted to in 2017, down 1.68 pp compared to the average over the last 5 years.
You can see all the company’s data at GlaxoSmithKline Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
